ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure (NASDAQ:NVCR) announced today that the Swiss Federal Office of Public Health (BAG) has added Optune in combination with temozolomide to the List of ...

Both companies target serious health challenges, but their financials and risk profiles reveal sharply different paths for ...

The Phase III TRIDENT study failed to show statistical significance in OS when Optune Gio was used earlier.

ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today announced that an abstract highlighting results from the EF-19 post-approval registry trial studying Optune for the treatment of ...

By Sneha S K June 18 (Reuters) - Novocure said on Thursday that a late-stage trial showed early use of its non-invasive cancer therapy did not significantly improve overall survival in patients with ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

NVCR wins Japan National Health Insurance reimbursement for Optune Lua in NSCLC patients. Coverage in Japan could expand patient access and drive adoption of Novocure's TTFields therapy platform. NVCR ...

A head patch device that delivers alternating electrical fields to the brain has been shown to significantly improve survival in newly diagnosed glioblastoma patients. Developed by Jersey, US-based ...

LITTLETON, Colo. (CBS4)- A man with stage 4 brain cancer is beating the odds. Bruce Stahlman has extended his life expectancy with a treatment at UCHealth: a portable, painless device. He wears a ...